首页> 美国卫生研究院文献>other >Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by Molecular Tweezers - from the Test Tube to Animal Models
【2h】

Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by Molecular Tweezers - from the Test Tube to Animal Models

机译:通过分子镊子破坏淀粉样蛋白低聚物的自组装和毒性-从试管到动物模型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite decades of research, therapy for diseases caused by abnormal protein folding and aggregation (amyloidoses) is limited to treatment of symptoms and provides only temporary and moderate relief to sufferers. The failure in developing successful disease-modifying drugs for amyloidoses stems from the nature of the targets for such drugs – primarily oligomers of amyloidogenic proteins, which are distinct from traditional targets, such as enzymes or receptors. The oligomers are metastable, do not have well-defined structures, and exist in dynamically changing mixtures. Therefore, inhibiting the formation and toxicity of these oligomers likely will require out-of-the-box thinking and novel strategies. We review here the development of a strategy based on targeting the combination of hydrophobic and electrostatic interactions that are key to the assembly and toxicity of amyloidogenic proteins using lysine (K)-specific “molecular tweezers” (MTs). Our discussion includes a survey of the literature demonstrating the important role of K residues in the assembly and toxicity of amyloidogenic proteins and the development of a lead MT derivative called CLR01, from an inhibitor of protein aggregation in vitro to a drug candidate showing effective amelioration of disease symptoms in animal models of Alzheimer’s and Parkinson’s diseases.
机译:尽管进行了数十年的研究,但由异常蛋白质折叠和聚集(淀粉样蛋白)引起的疾病的治疗仅限于症状的治疗,只能为患者提供暂时和中度的缓解。开发成功的淀粉样变性疾病改良药物的失败源于此类药物靶标的性质-主要是淀粉样蛋白原蛋白的寡聚物,与传统靶标(如酶或受体)不同。低聚物是亚稳的,没有明确的结构,并且以动态变化的混合物形式存在。因此,抑制这些低聚物的形成和毒性可能需要开箱即用的思路和新颖的策略。我们在此回顾一种策略的开发,该策略基于靶向疏水和静电相互作用的组合,这对于使用赖氨酸(K)特异的“分子镊子”(MTs)产生淀粉样蛋白的组装和毒性至关重要。我们的讨论包括对文献的调查,这些文献证明了K残基在淀粉样蛋白的组装和毒性中的重要作用,以及一种称为CLR01的MT衍生物的发展,从体外的蛋白质聚集抑制剂发展到可有效改善K的候选药物。阿尔茨海默氏病和帕金森氏病动物模型中的疾病症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号